Literature DB >> 18040821

Translational research models and novel adjunctive therapies for neuroAIDS.

M Christine Zink1.   

Abstract

The goal of this component of the meeting was to discuss novel therapeutics that attenuate inflammatory pathways, enhance drug delivery into the brain and/or bypass the blood-brain barrier (BBB). Presentations included discussions of (i) antiretroviral drugs packaged into nanoparticles by Howard Gendelman, (ii) how to engage the nasal epithelium and its closely associated neural fibers as a route for drug entry to the brain, by William H. Frey and Lynn Pulliam, and (iii) antioxidant gene delivery to neurons using vector systems that can protect neurons against HIV-associated toxicity, by David Strayer. The session was capped by active discourse among leaders in the field of adjunctive therapies in a broad range of scientific disciplines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18040821     DOI: 10.1007/s11481-006-9062-y

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  6 in total

1.  Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery.

Authors:  Huanyu Dou; Christopher J Destache; Justin R Morehead; R Lee Mosley; Michael D Boska; Jeffrey Kingsley; Santhi Gorantla; Larisa Poluektova; Jay A Nelson; Mahesh Chaubal; Jane Werling; James Kipp; Barrett E Rabinow; Howard E Gendelman
Journal:  Blood       Date:  2006-06-29       Impact factor: 22.113

2.  Antioxidant enzyme gene delivery to protect from HIV-1 gp120-induced neuronal apoptosis.

Authors:  L Agrawal; J-P Louboutin; B A S Reyes; E J Van Bockstaele; D S Strayer
Journal:  Gene Ther       Date:  2006-07-27       Impact factor: 5.250

3.  HIV-1 Tat inhibits neprilysin and elevates amyloid beta.

Authors:  Hans C Rempel; Lynn Pulliam
Journal:  AIDS       Date:  2005-01-28       Impact factor: 4.177

Review 4.  Human immunodeficiency virus-mononuclear phagocyte interactions: emerging avenues of biomarker discovery, modes of viral persistence and disease pathogenesis.

Authors:  Pawel Ciborowski; Howard E Gendelman
Journal:  Curr HIV Res       Date:  2006-07       Impact factor: 1.581

Review 5.  Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS.

Authors:  Leah R Hanson; William H Frey
Journal:  J Neuroimmune Pharmacol       Date:  2006-09-15       Impact factor: 4.147

Review 6.  Nanotechnology: a focus on nanoparticles as a drug delivery system.

Authors:  Jeffrey D Kingsley; Huanyu Dou; Justin Morehead; Barrett Rabinow; Howard E Gendelman; Christopher J Destache
Journal:  J Neuroimmune Pharmacol       Date:  2006-09       Impact factor: 4.147

  6 in total
  4 in total

Review 1.  Editorial neuroAIDS review.

Authors:  Paul Shapshak; Pandjassarame Kangueane; Robert K Fujimura; Deborah Commins; Francesco Chiappelli; Elyse Singer; Andrew J Levine; Alireza Minagar; Francis J Novembre; Charurut Somboonwit; Avindra Nath; John T Sinnott
Journal:  AIDS       Date:  2011-01-14       Impact factor: 4.177

Review 2.  Gene therapy for the nervous system: challenges and new strategies.

Authors:  Casey A Maguire; Servio H Ramirez; Steven F Merkel; Miguel Sena-Esteves; Xandra O Breakefield
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

3.  N-(Pivaloyloxy)alkoxy-carbonyl Prodrugs of the Glutamine Antagonist 6-Diazo-5-oxo-l-norleucine (DON) as a Potential Treatment for HIV Associated Neurocognitive Disorders.

Authors:  Michael T Nedelcovych; Lukáš Tenora; Boe-Hyun Kim; Jennifer Kelschenbach; Wei Chao; Eran Hadas; Andrej Jančařík; Eva Prchalová; Sarah C Zimmermann; Ranjeet P Dash; Alexandra J Gadiano; Caroline Garrett; Georg Furtmüller; Byoungchol Oh; Gerald Brandacher; Jesse Alt; Pavel Majer; David J Volsky; Rana Rais; Barbara S Slusher
Journal:  J Med Chem       Date:  2017-08-14       Impact factor: 8.039

Review 4.  Nose-to-Brain Delivery of Antiviral Drugs: A Way to Overcome Their Active Efflux?

Authors:  Alessandro Dalpiaz; Barbara Pavan
Journal:  Pharmaceutics       Date:  2018-03-26       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.